To this end, oncogenic KRAS-driven lung tumour models will be useful since the progression of early precursor lesions into malignant adenocarcinoma can be tracked in these models (Jackson et al, 2001; Mainardi et al, 2014). This evidence concerns the gene KRAS and adenocarcinoma.